A trial has found that patients with an aggressive subtype of non-Hodgkin’s lymphoma are likely to benefit from an epigenetic drug, US researchers have reported.
The drug, azacitidine, is currently used in the US for myelodysplastic syndrome and s...
11 months ago
The atmosphere at this year’s Annual Scientific Meeting (ASM) was a particularly energetic mix of excitement and anticipation, alongside some trenchant discussion of the challenges facing the haematology workforce.
As nearly 1,600 delegates desce...
11 months ago